There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Acrivon Therapeutics, Inc. (ACRV – Research Report), Insmed (INSM – Research Report) and Lumos Pharma (LUMO – Research Report) with bullish sentiments.
Acrivon Therapeutics, Inc. (ACRV)
H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Acrivon Therapeutics, Inc. today and set a price target of $20.00. The company’s shares closed last Tuesday at $12.10.
According to TipRanks.com, Bodnar is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Acrivon Therapeutics, Inc. with a $23.67 average price target.
See today’s best-performing stocks on TipRanks >>
Insmed (INSM)
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Insmed, with a price target of $52.00. The company’s shares closed last Tuesday at $26.37, close to its 52-week high of $27.15.
According to TipRanks.com, Fein ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Insmed has an analyst consensus of Strong Buy, with a price target consensus of $40.29, a 67.5% upside from current levels. In a report released yesterday, Guggenheim also maintained a Buy rating on the stock with a $52.00 price target.
Lumos Pharma (LUMO)
In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Lumos Pharma, with a price target of $28.00. The company’s shares closed last Tuesday at $3.12, close to its 52-week low of $2.63.
According to TipRanks.com, White is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Lumos Pharma with a $21.33 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ACRV:
- Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon’s AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies
- Acrivon Therapeutics initiated with a Buy at JonesResearch
- Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Acrivon Therapeutics expects cash to fund operations into 2025
- Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
